Download PDF
Drug Res (Stuttg) 2019; 69(05): 297-300
DOI: 10.1055/a-0748-5745
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes

Eiji Kutoh
1   Division of Clinical Research, Biomedical Center, Tokyo, Japan
2   Division of Diabetes and Endocrinology, Department of Internal Medicine, Gyoda General Hospital, Saitama, Japan
3   Division of Diabetes and Metabolism, Department of Internal Medicine, Higashitotsuka Memorial Hospital, Yokohama, Japan
,
Jyunka Hayashi
2   Division of Diabetes and Endocrinology, Department of Internal Medicine, Gyoda General Hospital, Saitama, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
08 October 2018 (online)

Also available at
   Permissions and Reprints

Abstract

This report describes the effect of administration (n=3) or withdrawal (n=2) of canagliflozin, a sodium-glucose co-transporters 2 (SGLT-2) inhibitor, on cardiac function in relation to ketone bodies. Three cases received and two cases discontinued canagliflozin. Changes of heart function with ultrasonography (EF: ejection fraction and %FS: functional shortening) and cardiometabolic parameters including ketone bodies (acetoacetate/beta-hydroxybutylate) were compared at 3 months. 69, 68 and 60 years old male patients A, B and C, respectively with moderately decreased heart function received canagliflozin 100 mg/day. EF, %FS and acetoacetate/beta-hydroxybutylate levels increased. 60 and 59 years old female patients D and E with normal and borderline heart function, respectively discontinued canagliflozin 50 mg/day. EF, %FS and acetoacetate/beta-hydroxybutylate levels decreased. Taken together, these results suggest that concomitant changes between ketone bodies and heart function were observed with or without canagliflzoin. This drug might have effects on cardiac function through modulating ketone bodies.

Key words

SGLT-2 inhibitors - canagliflozin - ketone body - heart function
 

  • References

  • 1 Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60: 215-225
    CrossrefPubMedGoogle Scholar
  • 2 Stenlöf K, Cefalu WT, Kim KA. et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-378
    CrossrefPubMedGoogle Scholar
  • 3 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
    CrossrefPubMedGoogle Scholar
  • 4 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
    CrossrefPubMedGoogle Scholar
  • 5 Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the empa-reg outcome study? a unifying hypothesis. Diabetes Care 2016; 39: 1115-1122
    CrossrefPubMedGoogle Scholar
  • 6 Ferrannini E, Mark M, Mayoux E. Cv Protection in the Empa-Reg Outcome Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016; 39: 1108-1114
    CrossrefPubMedGoogle Scholar
  • 7 Kutoh E. Effect of tofogliflozin on cardiac function: Potential link between ketone bodies and the heart. J Endocrinol Metab 2017; 7: 94-97
    PubMedGoogle Scholar
  • 8 Sano M, Takei M, Shiraishi Y. et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 2016; 8: 844-847
    CrossrefPubMedGoogle Scholar
  • 9 Parsa C, Matsumoto A, Kim J. et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007
    CrossrefPubMedGoogle Scholar
  • 10 Taegtmeyer H. Failing heart and starving brain: ketone bodies to the rescue. Circulation 2016; 134: 265-266
    CrossrefPubMedGoogle Scholar
  • 11 Newman JC, Verdin E. β-hydroxybutyrate: Much more than a metabolite. Diabetes Res Clin Pract 2014; 106: 173-181
    CrossrefPubMedGoogle Scholar